Immediate Impact
2 from Science/Nature 60 standout
Citing Papers
Challenges and opportunities in NASH drug development
2023 Standout
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis
2023 Standout
Works of F Schaefer being referenced
SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| F Schaefer | 158 | 17 | 8 | 94 | 47 | 9 | 297 | |
| Roberta Martinoli | 196 | 17 | 7 | 108 | 25 | 10 | 327 | |
| David N. Erceg | 214 | 22 | 10 | 63 | 12 | 9 | 327 | |
| Xingshan Zhao | 124 | 25 | 3 | 70 | 7 | 13 | 253 | |
| Xinying Shan | 50 | 13 | 1 | 89 | 56 | 17 | 209 | |
| Fräncis G. Benedict | 169 | 12 | 6 | 51 | 13 | 10 | 294 | |
| Anna Laura Fantuzzi | 169 | 32 | 21 | 67 | 19 | 8 | 324 | |
| Werner P. Venetz | 63 | 44 | 1 | 24 | 19 | 9 | 297 | |
| Nan Taggart | 89 | 18 | 2 | 73 | 139 | 8 | 311 | |
| Charles E. Driscoll | 111 | 17 | 5 | 37 | 22 | 13 | 213 | |
| Kelly A. Dumke | 106 | 9 | 2 | 90 | 33 | 8 | 291 |
All Works
Loading papers...